711 reports of this reaction
1.5% of all MECLIZINE HYDROCHLORIDE reports
#14 most reported adverse reaction
VERTIGO is the #14 most commonly reported adverse reaction for MECLIZINE HYDROCHLORIDE, manufactured by Aurobindo Pharma Limited. There are 711 FDA adverse event reports linking MECLIZINE HYDROCHLORIDE to VERTIGO. This represents approximately 1.5% of all 45,890 adverse event reports for this drug.
Patients taking MECLIZINE HYDROCHLORIDE who experience vertigo should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
VERTIGO is a less commonly reported adverse event for MECLIZINE HYDROCHLORIDE, but still significant enough to appear in the safety profile.
In addition to vertigo, the following adverse reactions have been reported for MECLIZINE HYDROCHLORIDE:
The following drugs have also been linked to vertigo in FDA adverse event reports:
VERTIGO has been reported as an adverse event in 711 FDA reports for MECLIZINE HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
VERTIGO accounts for approximately 1.5% of all adverse event reports for MECLIZINE HYDROCHLORIDE, making it a notable side effect.
If you experience vertigo while taking MECLIZINE HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.